Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + fludarabine + busulfan
- Development stage
- Phase 3
- Lead developer
- Hackensack Meridian Health
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy and conditioning regimen comprising decitabine, fludarabine, and busulfan. Developed by Hackensack Meridian Health, this regimen is utilized as a reduced-intensity conditioning (RIC) protocol for patients with myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), who are candidates for allogeneic hematopoietic stem cell transplantation. Decitabine serves as a hypomethylating agent that may enhance the sensitivity of malignant cells to subsequent chemotherapy by modulating the epigenetic state of the leukemia cells. Fludarabine, a purine analog, provides potent immunosuppression to prevent graft rejection, while busulfan, an alkylating agent, provides myeloablation to clear the bone marrow for donor cells.
- Other names
- Decitabine with Fludarabine and Busulfan ConditioningDecitabine + Fludarabine + Busulfan RIC
02
Targets
DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on decitabine + fludarabine + busulfan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + fludarabine + busulfan.